PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
12.50%
Gross profit growth under 50% of TRVN's 185.26%. Michael Burry would be concerned about a severe competitive disadvantage.
-29.39%
Negative EBIT growth while TRVN is at 34.17%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-29.39%
Negative operating income growth while TRVN is at 34.17%. Joel Greenblatt would press for urgent turnaround measures.
-30.95%
Negative net income growth while TRVN stands at 36.30%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-22.58%
Negative EPS growth while TRVN is at 36.29%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-22.58%
Negative diluted EPS growth while TRVN is at 36.29%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
7.95%
Share count expansion well above TRVN's 0.07%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
7.95%
Diluted share count expanding well above TRVN's 0.07%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
-8.11%
Negative OCF growth while TRVN is at 23.75%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-7.95%
Negative FCF growth while TRVN is at 23.75%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Negative 3Y CAGR while TRVN stands at 1299.23%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
91.14%
10Y OCF/share CAGR above 1.5x TRVN's 7.80%. David Dodd would check if a superior product mix or cost edge drives this outperformance.
75.06%
Positive OCF/share growth while TRVN is negative. John Neff might see a comparative advantage in operational cash viability.
-16.88%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-109.23%
Negative 10Y net income/share CAGR while TRVN is at 47.46%. Joel Greenblatt sees a major red flag in long-term profit erosion.
62.10%
Positive 5Y CAGR while TRVN is negative. John Neff might view this as a strong mid-term relative advantage.
-51.96%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
-71.08%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-53.15%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-63.40%
Both show negative short-term equity/share CAGR. Martin Whitman suspects an industry slump or unprofitable expansions for both players.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.71%
Positive asset growth while TRVN is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.
-7.41%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
-6.71%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
37.48%
We increase R&D while TRVN cuts. John Neff sees a short-term profit drag but a potential lead in future innovations.
21.30%
We expand SG&A while TRVN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.